| 11.53 -0.36 (-3.03%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.21  |
1-year : | 21.42 |
| Resists | First : | 15.59 |
Second : | 18.34 |
| Pivot price | 12.66 |
|||
| Supports | First : | 11.14 | Second : | 9.27 |
| MAs | MA(5) : | 11.65  |
MA(20) : | 13.28 |
| MA(100) : | 17.69 |
MA(250) : | 19.97 |
|
| MACD | MACD : | -1.4 |
Signal : | -1.4 |
| %K %D | K(14,3) : | 16.7 |
D(3) : | 14.5 |
| RSI | RSI(14): 26.5 |
|||
| 52-week | High : | 27.62 | Low : | 11.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SDGR ] has closed above bottom band by 21.5%. Bollinger Bands are 13.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12 - 12.06 | 12.06 - 12.1 |
| Low: | 11.28 - 11.36 | 11.36 - 11.41 |
| Close: | 11.42 - 11.54 | 11.54 - 11.61 |
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Tue, 17 Feb 2026
Schrodinger (NASDAQ:SDGR) Reaches New 52-Week Low - Should You Sell? - MarketBeat
Tue, 17 Feb 2026
Schrodinger, Inc. (SDGR) Investor Outlook: Unpacking A 123% Potential Upside - DirectorsTalk Interviews
Wed, 11 Feb 2026
Schrödinger to report 2025 results after market close Feb. 25 - Stock Titan
Fri, 06 Feb 2026
Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Wed, 04 Feb 2026
With A 26% Price Drop For Schrödinger, Inc. (NASDAQ:SDGR) You'll Still Get What You Pay For - simplywall.st
Tue, 27 Jan 2026
Schrodinger, Inc. (SDGR) Investor Outlook: Unveiling a 60.98% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 65 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 109.4 (%) |
| Shares Short | 10,580 (K) |
| Shares Short P.Month | 9,370 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.36 |
| Profit Margin | -68.5 % |
| Operating Margin | -84.6 % |
| Return on Assets (ttm) | -16.2 % |
| Return on Equity (ttm) | -45.7 % |
| Qtrly Rev. Growth | 53.9 % |
| Gross Profit (p.s.) | 2.31 |
| Sales Per Share | 3.98 |
| EBITDA (p.s.) | -2.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -4.81 |
| PEG Ratio | 0 |
| Price to Book value | 2.64 |
| Price to Sales | 2.89 |
| Price to Cash Flow | -664.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|